Ohio State is in the process of revising websites and program materials to accurately reflect compliance with the law. While this work occurs, language referencing protected class status or other activities prohibited by Ohio Senate Bill 1 may still appear in some places. However, all programs and activities are being administered in compliance with federal and state law.

COFS CIR Chat Session - Alyssa Fairgrieve

Alyssa Fairgrieve headshot
April 10, 2024
5:30 pm - 7:00 pm
Smith Lab Room 1009

Alyssa Fairgrieve is a third year Choose Ohio First (COF) Innovators for a New STEMM Workforce (INSW) scholar majoring in Biochemistry and minoring in Mathematics at The Ohio State University. Her interest lies in utilizing immunology and biomolecular engineering for disease treatment. In August of 2023, Alyssa joined the Liu Group for Biopharmaceutical Research and Biomanufacturing in the William G. Lowrie Department of Chemical and Biomolecular Engineering, where she has begun work on her undergraduate research thesis under Dr. Margaret X. Liu. The Liu Group develops targeted anti-cancer therapies, specifically monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), and gene therapies. This technology is developed for a variety of cancers in the lab; Alyssa’s specific focus is triple-negative breast cancers (TNBCs). The Liu Group is Alyssa’s second research experience, as she holds two years of prior experience in Lilly Lab at Nationwide Children’s Hospital (Columbus, OH), where she studied communication between smooth muscle cells and endothelial cells in the cardiovascular system, and the role of this communication in Alagille Syndrome and diabetes. 

From these experiences, Alyssa has gained a variety of lab skills. Her current project is a culmination of her time spent learning and working in the lab and her desire to make worthwhile contributions to biomedicine. 

Alyssa will present her research experiences at her CIR Chat Session on Wednesday, April 10, 2024 from 5:30PM - 6:30PM in Smith Lab Room 1009 (SM1009).